Mouse Thomsen-Friedenreich Antigen /CD176 Monoclonal Antibody

Thomsen-Friedenreich Antigen /CD176 (Pan Carcinoma Marker) Mouse Monoclonal Antibody

Cat. Num. AAA438664

• Reactivity: Human, Mouse, Rat
• Applications: Immunofluorescence, Immunohistochemistry
• Synonyms: Thomsen-Friedenreich Antigen /CD176; Monoclonal Antibody; Thomsen-Friedenreich Antigen /CD176 (Pan Carcinoma Marker) Mouse Monoclonal Antibody; T-F Antigen; TF Antigen; Asialoglycophorin; pan-carcinoma marker; CD176; anti-Thomsen-Friedenreich Antigen /CD176 antibody

• Host: Mouse
• Reactivity: Human, Mouse, Rat
• Clonality: Monoclonal
• Isotype: IgM, kappa
• Clone Number: SPM320
• Specificity: Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. This MAb is capable to agglutinate desialylated red blood cells. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide.
• Form/Format: 200ug/ml of Ab purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

• Applicable Applications for anti-Thomsen-Friedenreich Antigen /CD176 antibody: Immunofluorescence (IF), Immunohistochemistry (IHC) Formalin
• Application Notes: Immunofluorescence (1-2ug/ml); Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT); (Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes); Optimal dilution for a specific application should be determined.
• Cellular Localization: Cell Surface
• Immunogen: Neuraminidase-treated human red blood cells
• Positive Control: KG1 cells or human Colon Carcinoma
• Preparation and Storage: Antibody with azide - store at 2 to 8 degree C. Non-hazardous. No MSDS required.

Immunohistochemistry (IHC)

(Formalin-fixed, paraffin-embedded human Colon Carcinoma stained with Thomsen-Friedenreich Monoclonal Antibody (SPM320) at 4ug/ml.Antigen retrieval in 10mM Citrate buffer, pH 6.0; ABC detection system with DAB Chromogen.Note Cell Surface staining of epithelial cells.)

References

Karsten U et al. A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma 1995, 14(1):37-44 Cao Y. et al., Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197-207 (1996). Baldus SE et al. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 1998, 82(6):1019-27 Ryder SD et al.Peanut ingestion increases rectal proliferation in individuals with mucosal expression of peanut lectin receptor. Gastroenterology 1998, 114(1):44-9 Kanitakis J et al. Differential expression of the cancer associated antigens T (Thomsen-Friedenreich) and Tn to the skin in primary and metastatic carcinomas. J Clin Pathol 1998, 51(8):588-92.